- Home
- SOHU vs NMRA Comparison
SOHU vs NMRA Comparison
Compare SOHU & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOHU | NMRA |
|---|---|---|
| Founded | 1996 | 2019 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.1M | 302.0M |
| IPO Year | 2018 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SOHU | NMRA |
|---|---|---|
| Price | $13.62 | $1.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $20.00 | $7.50 |
| AVG Volume (30 Days) | 58.0K | ★ 687.0K |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.61 | N/A |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | $1.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.61 | $0.83 |
| 52 Week High | $17.30 | $3.65 |
Technical Indicators
Market Signals| Indicator | SOHU | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 28.21 |
| Support Level | $13.38 | $0.83 |
| Resistance Level | $13.61 | $1.74 |
| Average True Range (ATR) | 0.50 | 0.09 |
| MACD | -0.12 | -0.03 |
| Stochastic Oscillator | 19.34 | 0.96 |
Price Performance
Historical ComparisonAbout SOHU Sohu.com Limited
Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.